varside® 160mg tableta recubierta
corporacion biotec s.a.c. - droguerÍa - valsartan; - tableta recubierta - por vial - - valsartán
dermaside b 3.5mg+400 u.i.+5000u.i./g. unguento
sherfarma s.a.c. - droguerÍa - unguento - por gragea - - neomicina, combinaciones
varside 80mg tableta recubierta
corporacion biotec s.a.c. - droguerÍa - valsartan; - tableta recubierta - por mililitro 80.00 mg - - valsartán
varside 80mg tableta recubierta
corporacion biotec s.a.c. - tableta recubierta
varside® 160mg tableta recubierta
corporacion biotec s.a.c. - tableta recubierta
dermaside unguento
sherfarma s.a.c. - sulfato de neomicina; bacitracina; polimixina b; - unguento - por otros100 g; sulfato de neomicina 0.500000 g; bacitracina 50.000000 ui; polimixina b 500.000000 ui; - neomicina, combinaciones
dermaside unguento
sherfarma s.a.c. - unguento
passive middle ear implant - tympanoplasty prosthesis, marca: med el
medical audicion peru s.a.c. -
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
design massive brillo encendido. lo ultimo en brillo para tu cabello
ondabel chile s.a. - sin formulas